secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2023-02-24T23:59:59+00:00
Accession:  0001558370-23-001964
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio reports PBGM01 interim data: MRI stabilization, biomarker decreases in GM1 gangliosidosis trial
--------------------------------------------------------------------------------

- All six treated patients showed stabilization of MRI severity scores over 6-12 months follow-up.
- High-dose PBGM01 resulted in 3.6-5.2x increase in CSF β-gal activity, sustained up to 12 months.
- No treatment-related serious adverse events, DRG toxicity, or complications from ICM delivery.
- Urine Dp5 levels decreased in high-dose patients, indicating peripheral β-gal activity.
- Milder developmental delay at baseline associated with improved treatment response.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000155837023001964/0001558370-23-001964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000155837023001964/pasg-20230224x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-001964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer